Blueprint studio · Spec sheets · Amber callouts · Free shipping over $75

technospeak.fr Blueprint · Rev.39

Sheet A · Product board

bpc 157 tb500 capsules BPC-157 & TB-500 Select Syringe Size x Gauge x Needle Length:1cc x 28g x 1/2

Unit price

USD29.92

USD65.92

Pay in 4 interest-free payments of $7.48 Learn more

Field rating

4.7

Verified studio score · Spec revision current

Fit · Size

bpc 157 tb500 capsules

bpc 157 tb500 capsules BPC-157 & TB-500 Select Syringe Size x Gauge x Needle Length:1cc x 28g x 1/2" filter-range: General Living TORQ G2 Medium 1.0

SKU: 86260611867

Dispatch

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Oct 31 - Nov 5

Description

bpc 157 tb500 capsules BPC-157 & TB-500 Select Syringe Size x Gauge x Needle Length:1cc x 28g x 1/2" filter-range: General Living TORQ G2 Medium 1.0

TORQ G2 Medium 1.0 Body (1000 ml - 34 oz) Dual - NYOS

Inactive ingredients: Glacial acetic acid Sodium chloride Water for injections

filter-range: General Living

Select Syringe Size x Gauge x Needle Length:1cc x 28g x 1/2"

Caution Consult your doctor

Exchange/Return Notes

We offer a 30-day return/exchange service after receiving.
Final sale items are not eligible for returns or exchanges.
To process your return/exchange, please contact us at [email protected]
Please click here for more details>>> Return & Exchange Policy

You may also like

BPC-157 – No Proof Required! | Office for Science and Society

BPC-157 – No Proof Required! | Office for Science and Society

US$ 28.28

4.3 (27 reviews)

The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity

The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity

US$ 25.43

5.0 (11 reviews)

BPC-157 Explained: UK Guide to Research, Science & Evidence

BPC-157 Explained: UK Guide to Research, Science & Evidence

US$ 22.24

5.0 (26 reviews)

bpc-157 randomized controlled trial human bpc 157 clinical 2025 trials back pain BPC-157 For Knee Pain: Early Reported Outcomes, A 544 published articles on BPC-157. – bpc 157 human studies – BPC-157 Canada Research Guide 2026: –

bpc-157 randomized controlled trial human bpc 157 clinical 2025 trials back pain BPC-157 For Knee Pain: Early Reported Outcomes, A 544 published articles on BPC-157. – bpc 157 human studies – BPC-157 Canada Research Guide 2026: –

US$ 21.98

4.3 (29 reviews)

BPC-157: A Comprehensive Research Overview – Tides Lab Australia

BPC-157: A Comprehensive Research Overview – Tides Lab Australia

US$ 24.60

4.2 (22 reviews)

BPC-157 and other peptides are everywhere in the fitness world right now. The anecdotal reports (and some early research) are exciting! But, we still need to approach BPC-157 with caution. Right now

BPC-157 and other peptides are everywhere in the fitness world right now. The anecdotal reports (and some early research) are exciting! But, we still need to approach BPC-157 with caution. Right now

US$ 29.60

4.2 (21 reviews)

Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing | Cell and Tissue Research

Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing | Cell and Tissue Research

US$ 22.30

4.7 (5 reviews)

PDF) Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing

PDF) Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing

US$ 28.85

4.0 (5 reviews)

Frontiers

Frontiers

US$ 26.05

5.0 (9 reviews)

Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review

Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review

US$ 27.22

4.5 (21 reviews)

Frontiers

Frontiers

US$ 29.51

4.5 (10 reviews)

In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results

In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results

US$ 28.59

4.1 (20 reviews)

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1

US$ 20.62

4.9 (18 reviews)

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review | Pharmaceutical Research

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review | Pharmaceutical Research

US$ 27.09

4.9 (20 reviews)

Statins and cognitive decline in patients with Alzheimer's and mixed dementia: a longitudinal registry-based cohort study | Alzheimer's Research & Therapy

Statins and cognitive decline in patients with Alzheimer's and mixed dementia: a longitudinal registry-based cohort study | Alzheimer's Research & Therapy

US$ 26.76

4.9 (6 reviews)

dosing for cagrilintide with retatrutide dosage Once-weekly cagrilintide weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Cagrilintide

dosing for cagrilintide with retatrutide dosage Once-weekly cagrilintide weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Cagrilintide

US$ 25.50

4.9 (15 reviews)

Cagrilintide-Semaglutide Could Improve Glycemic Control in Type 2 Diabetes Patients on Basal Insulin

Cagrilintide-Semaglutide Could Improve Glycemic Control in Type 2 Diabetes Patients on Basal Insulin

US$ 29.77

4.2 (16 reviews)

Do Statins Cause Dementia? A Cardiologist Reviews the Evidence

Do Statins Cause Dementia? A Cardiologist Reviews the Evidence

US$ 27.36

4.5 (18 reviews)

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials - Hamarsheh - 2026 - Endocrinology, Diabetes & Metabolism

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials - Hamarsheh - 2026 - Endocrinology, Diabetes & Metabolism

US$ 25.89

4.9 (20 reviews)

Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3

Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3

US$ 20.17

4.0 (20 reviews)